Reference is made to the stock exchange notice published on 7 June 2015 regarding the closing of a private placement with gross proceeds of NOK 37.1 million (the "Private Placement") and the closing of a bond loan with gross proceeds of NOK 67.6 million.
The share capital increase related to the Private Placement has now been registered with the Norwegian Register of Business Enterprises.
The share capital has been increased with NOK 12,373,478 through issuance of a corresponding amount of new shares. The new share capital is thus NOK 110,409,566 divided by 110,409,566 shares, each with a par value of NOK 1.
The new shares will be listed and become tradable on Oslo Axess as soon as possible after a listing prospectus has been approved by the Norwegian Financial Supervisory Authority. The new shares will be temporarily issued on a separate ISIN and will not be tradable until the abovementioned listing prospectus has been approved.
For further information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Tel +47 936 32 966
E-mail: joo@hofsethbiocare.no
Øystein Omvik, CFO Hofseth BioCare ASA
Tel: +47 936 99 400
E-mail: oystein.omvik@hofsethbiocare.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biomarine company with the key objective to provide high value added biomarine ingredients for human applications. The Company is founded on the core value of sustainability and optimal use of natural resources. Through innovative production technology and logistics, Hofseth BioCare is able to preserve the quality of protein, calcium and oil extracted from fish off-cuts. Products that previously could only be used as animal feed can now be made suitable for human consumption. HBC's objective is thus to contribute to efficient use of marine resources and entering the higher profit market of quality ingredients for human applications.